AAEP Annual Convention Salt Lake City 2014
Back to Table of Contents
Add to My Library
Comments
Share:

Tiludronate Disodium in the Management of Lameness Associated With Equine Navicular Syndrome

Author(s):

V.S. Williams, A.K. Allen

In: AAEP Annual Convention - Salt Lake City, 2014 by American Association of Equine Practitioners
Updated:
DEC 10, 2014
Languages:
Back to Table of Contents
Add to My Library

Intravenous tiludronate disodium significantly improved lameness associated with navicular syndrome. Authors’ addresses: Ceva Animal Health, LLC, 8735 Rosehill Rd., Suite 300, Lenexa, KS 66215 (Williams); and Virginia Equine Imaging, 2716 Landmark School Road, The Plains, VA 20198 (Allen); e-mail: valentine.williams@ceva.com.

1. Introduction

Navicular syndrome is a common cause of lameness and disability in performance horses. The objective of this study was to examine the effectiveness of the bisphosphonate tiludronate disodiuma plus corrective shoeing on lameness associated with navicular syndrome in a blinded randomized placebo controlled clinical trial.

2. Materials and Methods

Cases were selected based on lameness examination (AAEP lameness score of 2 or 3), palmar digital nerve blocks, radiographic findings, and magnetic resonance imaging findings (navicular bone edema with minimal soft tissue lesions). Suitable cases were randomly assigned to a single treatment with tiludronate disodium (1.0 mg/kg) or control (250 mg mannitol) in 1 liter of 0.9% saline administered by intravenous infusion over 30 or 60 minutes. All horses were subjected to corrective shoeing. Effectiveness was defined as an improvement of ≥1 grade lameness score in the lamest limb with no worsening of lameness in the opposite limb at 2 months post treatment. 

3. Results

Located at 12 sites, 181 cases (119 treated group and 62 control group) complied with all requirements for inclusion in data analysis. Tiludronate disodium was significantly more effective compared to the control group in reducing lameness score (64% vs 48%, respectively).

4. Discussion

Tiludronate disodium in conjunction with corrective shoeing effectively reduced lameness associated with navicular syndrome.

Acknowledgments

The authors thank all investigators who provided cases for this study: Drs. Erin Denney-Jones, Ron Genovese, Jake Hersman, Carter Judy, Douglas Langer, Paul McClellan, Rick Mitchell, Robert Schneider, Scott Taylor, Kelly Tisher, and Chad Zubrod.

Conflict of Interest

This study was funded by Ceva Santé Animale. Dr. Williams is employed by Ceva Animal Health, LLC, the U.S. subsidiary of the sponsor.

Footnote

a Tildren, Ceva Sante Animale, 33500 Libourne, France.

View full text
Back to Table of Contents
Add to My Library

Ask the author

0 comments
Submit

Affiliation of the authors at the time of publication

Ceva Animal Health, LLC, 8735 Rosehill Rd., Suite 300, Lenexa, KS 66215 (Williams); and Virginia Equine Imaging, 2716 Landmark School Road, The Plains, VA 20198 (Allen)

Copyright Statement

© All text and images in this publication are copyright protected and cannot be reproduced or copied in any way.

Readers also viewed these publications

Provided by:

The AAEP represents nearly 9,300 veterinarians and veterinary students in 61 countries who cover a broad range of equine disciplines, breeds and associations. The AAEP is primary resource for education, professional development and ethical standards for its members. The AAEP and its members are recognized as the voice and authority for the health and welfare of the horse. The AAEP conducts regular strategic planning every three to four years in order to establish priorities and set direction for the association over the current planning horizon.  The AAEP is a respected source of information for influencing public policy.  

Learn more
Back To Top